144 related articles for article (PubMed ID: 34352996)
1. Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study.
Kim YR; Kim SJ; Lee HS; Jeon S; Cho H; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
Cancer Res Treat; 2022 Apr; 54(2):613-620. PubMed ID: 34352996
[TBL] [Abstract][Full Text] [Related]
2. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Niparuck P; Chuncharunee S; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasri N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T;
Hematol Oncol; 2019 Dec; 37(5):578-585. PubMed ID: 31702065
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.
Cao Z; Wang X; Xue X; Feng X
Ann Hematol; 2024 Mar; 103(3):869-883. PubMed ID: 38040859
[TBL] [Abstract][Full Text] [Related]
4. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
Maurer MJ; Ellin F; Srour L; Jerkeman M; Bennani NN; Connors JM; Slack GW; Smedby KE; Ansell SM; Link BK; Cerhan JR; Relander T; Savage KJ; Feldman AL
J Clin Oncol; 2017 Dec; 35(36):4019-4026. PubMed ID: 29072976
[TBL] [Abstract][Full Text] [Related]
5. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
6. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Chen H; Qin Y; Yang J; Liu P; Zhang C; He X; Zhou S; Yang S; Gui L; Zhou L; Sun Y; Shi Y
Ann Hematol; 2020 Dec; 99(12):2847-2857. PubMed ID: 32712792
[TBL] [Abstract][Full Text] [Related]
7. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
[TBL] [Abstract][Full Text] [Related]
8. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
Maurer MJ; Jais JP; Ghesquières H; Witzig TE; Hong F; Haioun C; Thompson CA; Thieblemont C; Micallef IN; Porrata LF; Ribrag V; Nowakowski GS; Casasnovas O; Bologna S; Morschhauser F; Morrison VA; Peterson BA; Macon WR; Copie-Bergman C; Feldman AL; Syrbu SI; Kurtin PJ; Gascoyne RD; Li H; Allmer C; Kahl BS; Ansell SM; Slager SL; Link BK; Salles G; Habermann TM; Tilly H; Cerhan JR
Am J Hematol; 2016 Feb; 91(2):179-84. PubMed ID: 26492520
[TBL] [Abstract][Full Text] [Related]
9. Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
Abu Sabaa A; Mörth C; Hasselblom S; Hedström G; Flogegård M; Stern M; Andersson PO; Glimelius I; Enblad G
Br J Haematol; 2021 Jun; 193(5):906-914. PubMed ID: 33948942
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
12. Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Niparuck P; Chuncharunee S; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasi N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T
Leuk Lymphoma; 2020 Nov; 61(11):2614-2621. PubMed ID: 32573294
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma.
Goldschmidt N; Darawshy F; Kleinstern G; Slyusarevsky E; Pogrebijski G; Krichevsky S; Ben-Yehuda D; Gatt ME
Leuk Lymphoma; 2017 Jan; 58(1):45-52. PubMed ID: 27756163
[TBL] [Abstract][Full Text] [Related]
15. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
[No Abstract] [Full Text] [Related]
19. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.
Fujimoto A; Anzai T; Fukuda T; Uchida N; Ohta T; Mori T; Sawa M; Yoshioka S; Miyamoto T; Uchiyama H; Katayama Y; Matsuoka KI; Shiratori S; Nakazawa H; Kanda J; Ichinohe T; Atsuta Y; Fujita N; Kondo E; Suzuki R
Blood Adv; 2021 Mar; 5(5):1412-1424. PubMed ID: 33666656
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
